ArticleClinical pharmacology and therapeutics2026
Benchmark of Open-Access Star-Allele Callers to Accurately Assess Haplotypes and Phenotypes in Pharmacogenetic Studies.
Article in Clinical pharmacology and therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Characterization of NAT2 Using Long-Read Sequencing: Allele, Diplotype, and Phenotype Call Accuracy Compared to Other Testing Strategies.Clinical pharmacology and therapeutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Genetic polymorphisms are common in pharmacogenes, with sometimes important implications for drug metabolism. Assessing the correct enzyme phenotype from genetic data is thus a crucial step into the development of personalized medicine. Many bioinformatics star-allele callers have been developed for this purpose of identifying the correct star alleles and the associated phenotype, each of them having their specific method and limitations. Despite the important benchmarks that have been made so far, their performances have not yet been fully explored depending on various parameters, such as the type of genetic data provided as input or the individuals' ancestry. Hence, we provide a multi-gene, multi data-type comparison of the accuracy of four commonly used and open-access star-allele callers: PyPGx, ursaPGx, PharmCAT, and Aldy. We found that PyPGx and Aldy are overall more performant than the others, except for CYP2D6 where ursaPGx was the most accurate with its CYP2D6 dedicated caller that relies on the Cyrius software. Comparing to the commercial solution DRAGEN, PyPGx, and Aldy showed better results, except for CYP2D6 where DRAGEN performed best. When only SNP-chip or low-pass sequencing data is available, the use of imputation greatly improves the performance of star-allele callers, allowing performance comparable to that achieved with sequencing data. We also analyzed how concordance between star-allele callers varies depending on population ancestry. Our findings offer guidance on the choice of star-allele caller, depending on the pharmacogene being studied and the resolution of available genetic data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.